Clinical Trial: A Study Examining Maintenance Avastin Monotherapy in Patients With Advanced Lung Adenocarcinoma

Study Status: Recruiting
Recruit Status: Recruiting
Study Type: Observational

Official Title: A Multicenter, Prospective, Non-interventional Study of Maintenance Avastin (Bevacizumab) Following Induction Treatment With Platinum Doublet Plus Avastin in Patients With Advanced

  • PFS, defined as time from first dose of induction Avastin treatment until disease progression or death from any cause [ Time Frame: Up to 28 months ]
  • 1-year overall survival defined as time from first dose of induction Avastin treatment until death from any cause [ Time Frame: 12 months ]
  • Best overall response [ Time Frame: Up to 28 months ]
  • Incidence of adverse events [ Time Frame: Up to 28 months ]


    • Original Secondary Outcome:

    • PFS, defined as time from first dose of induction Avastin treatment until disease progression or death from any cause. [ Time Frame: Up to 34 months ]
    • 1 year overall survival defined as time from first dose of induction Avastin treatment until death from any cause. [ Time Frame: 12 months ]
    • Best overall response [ Time Frame: Up to 34 months ]
    • Incidence of adverse events [ Time Frame: Up to 34 months ]


    Information By: Hoffmann-La Roche

    Dates:
    Date Received: March 19, 2014
    Date Started: November 2014
    Date Completion: October 2017
    Last Updated: August 1, 2016
    Last Verified: August 2016